Michael P Whyte1, Edward Leung2, William R Wilcox3, Johannes Liese4, Jesús Argente5, Gabriel Á Martos-Moreno5, Amy Reeves6, Kenji P Fujita7, Scott Moseley8, Christine Hofmann4. 1. Center for Metabolic Bone Disease and Molecular Research, Shriners Hospital for Children, St Louis, MO; Division of Bone and Mineral Diseases, Department of Internal Medicine, Washington University School of Medicine at Barnes-Jewish Hospital, St Louis, MO. Electronic address: mwhyte@shrinenet.org. 2. Children's Hospital Research Institute of Manitoba, University of Manitoba, Winnipeg, Manitoba, Canada. 3. Department of Human Genetics, Emory University School of Medicine, Atlanta, GA. 4. University Children's Hospital, University of Würzburg, Würzburg, Germany. 5. Hospital Infantil Universitario Niño Jesús, Universidad Autónoma de Madrid, CIBERobn, ISCIII, IMDEA Food Institute, CEIUAM+CSIC, Madrid, Spain. 6. Center for Metabolic Bone Disease and Molecular Research, Shriners Hospital for Children, St Louis, MO. 7. Clinical Research, Alexion Pharmaceuticals, Inc, Boston, MA. 8. Biostatistics, Alexion Pharmaceuticals, Inc, Boston, MA.
Abstract
OBJECTIVE: To report clinical characteristics and medical history data obtained retrospectively for a large cohort of pediatric patients with perinatal and infantile hypophosphatasia. STUDY DESIGN: Medical records from academic medical centers known to diagnose and/or treat hypophosphatasia were reviewed. Patients born between 1970 and 2011 with hypophosphatasia and any of the following signs/symptoms at age <6 months were eligible: vitamin B6-dependent seizures, respiratory compromise, or rachitic chest deformity (NCT01419028). Patient demographics and characteristics, respiratory support requirements, invasive ventilator-free survival, and further complications of hypophosphatasia were followed for up to the first 5 years of life. RESULTS: Forty-eight patients represented 12 study sites in 7 countries; 13 patients were alive, and 35 were dead (including 1 stillborn). Chest deformity, respiratory distress, respiratory failure (as conditioned by the eligibility criteria), failure to thrive, and elevated calcium levels were present in >70% of patients between birth and age 5 years. Vitamin B6-dependent seizures and respiratory distress and failure were associated significantly (P < .05) with the risk of early death. Serum alkaline phosphatase activity in all 41 patients tested (mean [SD]: 18.1 [15.4] U/L) was below the mean lower limit of normal of the reference ranges of the various laboratories (88.2 U/L). Among the 45 patients with relevant data, 29 had received respiratory support, of whom 26 had died at the time of data collection. The likelihood of invasive ventilator-free survival for this cohort decreased to 63% at 3 months, 54% at 6 months, 31% at 12 months, and 25% at 5 years. CONCLUSIONS: Patients with perinatal or infantile hypophosphatasia and vitamin B6-dependent seizures, with or without significant respiratory distress or chest deformities, have high morbidity and mortality in the first 5 years of life. TRIAL REGISTRATION: ClinicalTrials.gov: NCT01419028.
OBJECTIVE: To report clinical characteristics and medical history data obtained retrospectively for a large cohort of pediatric patients with perinatal and infantile hypophosphatasia. STUDY DESIGN: Medical records from academic medical centers known to diagnose and/or treat hypophosphatasia were reviewed. Patients born between 1970 and 2011 with hypophosphatasia and any of the following signs/symptoms at age <6 months were eligible: vitamin B6-dependent seizures, respiratory compromise, or rachitic chest deformity (NCT01419028). Patient demographics and characteristics, respiratory support requirements, invasive ventilator-free survival, and further complications of hypophosphatasia were followed for up to the first 5 years of life. RESULTS: Forty-eight patients represented 12 study sites in 7 countries; 13 patients were alive, and 35 were dead (including 1 stillborn). Chest deformity, respiratory distress, respiratory failure (as conditioned by the eligibility criteria), failure to thrive, and elevated calcium levels were present in >70% of patients between birth and age 5 years. Vitamin B6-dependent seizures and respiratory distress and failure were associated significantly (P < .05) with the risk of early death. Serum alkaline phosphatase activity in all 41 patients tested (mean [SD]: 18.1 [15.4] U/L) was below the mean lower limit of normal of the reference ranges of the various laboratories (88.2 U/L). Among the 45 patients with relevant data, 29 had received respiratory support, of whom 26 had died at the time of data collection. The likelihood of invasive ventilator-free survival for this cohort decreased to 63% at 3 months, 54% at 6 months, 31% at 12 months, and 25% at 5 years. CONCLUSIONS:Patients with perinatal or infantile hypophosphatasia and vitamin B6-dependent seizures, with or without significant respiratory distress or chest deformities, have high morbidity and mortality in the first 5 years of life. TRIAL REGISTRATION: ClinicalTrials.gov: NCT01419028.
Authors: Juan Miguel Villa-Suárez; Cristina García-Fontana; Francisco Andújar-Vera; Sheila González-Salvatierra; Tomás de Haro-Muñoz; Victoria Contreras-Bolívar; Beatriz García-Fontana; Manuel Muñoz-Torres Journal: Int J Mol Sci Date: 2021-04-21 Impact factor: 5.923
Authors: Raja Padidela; Robert Yates; Dan Benscoter; Gary McPhail; Elaine Chan; Jaya Nichani; M Zulf Mughal; Charles Myer; Omendra Narayan; Claire Nissenbaum; Stuart Wilkinson; Shanggen Zhou; Howard M Saal Journal: Orphanet J Rare Dis Date: 2020-08-06 Impact factor: 4.123
Authors: Yuka Kinoshita; Fatma F Mohamed; Flavia Amadeu de Oliveira; Sonoko Narisawa; Koichi Miyake; Brian L Foster; José Luis Millán Journal: J Bone Miner Res Date: 2021-06-15 Impact factor: 6.741